CD79A and nasopharyngeal carcinoma: These markers include EBV (IgA) serology and EBV-DNA load since NPC patients have characteristic elevated IgG and IgA antibody titres to several EBV encoded antigens as well as increased EBV-DNA derived from shed (apoptotic) fragments from the tumour into the circulation.